Skip to main content

Featured

The CUSMA Countdown: 24 Days to a Trade Deadline That Could Hit Your Wallet

Canada's free trade deal with the U.S. hits a mandatory review milestone on July 1. With negotiations unresolved and Washington demanding changes, here's what it actually means for your groceries, your car, and your job. MoneySavings.ca Staff Canadian Money Brief June 7, 2026 5 min read What Is CUSMA and Why Does July 1 Matter? CUSMA — the Canada-United States-Mexico Agreement — is the trade deal that keeps the North American economy humming. It replaced NAFTA in 2020 and governs the movement of trillions of dollars in goods and services across the Canada-U.S. border every year. For Canadian consumers, it's largely invisible — until it isn't. Built into the agreement is a mandatory six-year joint review, and that clock expires on July 1, 2026 . By that date, all three countries must declare whether they want to renew the deal for another 16 years, trigger annual reviews, or walk away. Whatever they decide, CUSMA technically stays in force until 2036 — but the path chose...
Post a Comment
Read more

article

Labels

Controversial Turkish Import Endangers Newborns in Alberta, Documents Reveal

 

Recent documents have raised alarming concerns over Alberta’s emergency importation of children’s pain medication from Turkey. Produced by Atabay Pharmaceuticals and sold under the brand name Parol Suspension, the drug is marketed at a concentration of 24 mg/ml—significantly lower than the 32 mg/ml concentration found in the standard, Canadian-authorized formulation.

Health experts and opposition critics warn that this altered concentration poses a twofold risk. First, the discrepancy could lead to dosing errors if parents and caregivers, accustomed to the standard formulation, misjudge the correct volume needed. Second, there are fears that the lower concentration may lead to the clogging of hospital feeding tubes—a critical concern for vulnerable newborns.

Alberta Blue Cross has informed pharmacists that Parol must be dispensed with enhanced caution, requiring additional education on its proper use. Critics argue that the rushed procurement—amounting to approximately $80 million—exemplifies a misstep in prioritizing political expedience over stringent safety protocols. With traditional supplies of children’s pain medications already in short supply, many worry that this controversial alternative might jeopardize the health of Alberta’s youngest patients.

Further review and tighter regulatory oversight are now being called for, as stakeholders demand that the province safeguard the well-being of newborns and ensure that emergency measures do not compromise pediatric care.

Labels:

Comments

Post a Comment